Blincyto treats a certain type of leukemia. Before you receive this medication, you may be given a corticosteroid medicine to help reduce infusion reactions.
Blincyto is a prescription medicine used to treat a certain type of acute lymphoblastic leukemia (ALL). Acute lymphoblastic leukemia is a cancer of the blood in which a particular kind of white blood cell is growing out of control.
Blincyto is a type of immunotherapy, a treatment that uses certain parts of a person’s immune system to destroy leukemia cells.
This medication comes in an injectable form to be given directly into the vein by continuous IV infusion for 4 weeks (28 days), followed by a 2 week break.
Common side effects include fever, headache and accumulation of fluid in the lower limbs. Do not drive, operate heavy machinery, or do other dangerous activities while you are receiving Blincyto as it may cause dizziness, seizures, and confusion.
Patient Ratings for
How was your experience with ?
Blincyto Cautionary Labels
Uses of Blincyto
Blincyto is a prescription medicine used to treat a certain type of acute lymphoblastic leukemia (ALL). Blincyto is approved to treat patients with:
- B-cell precursor acute lymphoblastic leukemia (ALL) in remission with a certain type of evidence of leukemia
- B-cell precursor ALL that has come back or did not respond to previous treatments
This medication may be prescribed for other uses. Ask your doctor or pharmacist for more information.
Blincyto Drug Class
Blincyto is part of the drug class:
Side Effects of Blincyto
The most common side effects of Blincyto include:
- swelling of hands, ankles or feet
Tell your healthcare provider if you have any side effect that bothers you or that does not go away.
These are not all the possible side of effects of Blincyto.
Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Especially tell your healthcare provider if you take:
This is not a complete list of Blincyto drug interactions. Ask your doctor or pharmacist for more information.
Blincyto may cause serious side effects that can be severe, life- threatening, or lead to death, including:
Cytokine Release Syndrome (CRS) and Infusion Reactions. Symptoms of CRS and infusion reactions may include:
- tiredness or weakness
- low blood pressure
- face swelling
- wheezing or trouble breathing
- skin rash
Neurologic problems. Symptoms of neurologic problems may include:
- difficulty in speaking or slurred speech
- loss of consciousness
- confusion and disorientation
- loss of balance
Do not drive or engage in hazardous occupations or activities such as operating heavy or potentially dangerous machinery while this medication is being administered.
Blincyto may cause other serious side effects, including:
- Infections. Blincyto may cause life-threatening infections that may lead to death. Tell your healthcare provider right away if you develop an infection.
- Low white blood cell counts (neutropenia). Neutropenia is common with Blincyto treatment and may sometimes be life-threatening. Low white blood cell counts can increase your risk of infection. Tell your healthcare provider right away if you get a fever.
- Abnormal liver blood test. Your healthcare provider will do blood tests before you start Blincyto and during treatment with Blincyto to check your liver.
- Inflammation of the pancreas. Tell your healthcare provider right away if you have severe stomach-area pain that does not go away. The pain may happen with or without nausea and vomiting.
Your healthcare provider will check you for these problems during treatment with Blincyto. Your healthcare provider may temporarily stop or completely stop your treatment with Blincyto if you have severe side effects.
Do not receive Blincyto if you are allergic to Blincyto or to any of the ingredients of Blincyto.
Blincyto Food Interactions
Medicines can interact with certain foods. In some cases this may be harmful and your doctor may advise you to avoid certain foods. In the case of Blincyto, there are no specific foods that you must exclude from your diet when receiving this medication.
Before you receive Blincyto, tell your healthcare provider about all of your medical conditions, including if you:
- are allergic to Blincyto or to any of its ingredients
- have a history of neurological problems, such as seizures, confusion, trouble speaking or loss of balance.
- have an infection.
- have ever had an infusion reaction after receiving Blincyto or other medications.
- have a history of radiation treatment to the brain, or chemotherapy treatment
- are scheduled to receive a vaccine. You should not receive a “live vaccine” within 2 weeks before you start treatment with Blincyto, during treatment, and until your immune system recovers after you receive your last cycle of Blincyto. If you are not sure about the type of vaccine, ask your healthcare provider.
- are pregnant or plan to become pregnant. Blincyto may harm your unborn baby. Tell your healthcare provider if you become pregnant during treatment with Blincyto.
- are breastfeeding or plan to breastfeed. It is not known if Blincyto passes into your breast milk. You and your healthcare provider should decide if you will take Blincyto or breastfeed. You should not do both.
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
Blincyto and Pregnancy
Tell your healthcare provider if you are pregnant or plan to become pregnant.
The FDA categorizes medications based on safety for use during pregnancy. Five categories - A, B, C, D, and X are used to classify the possible risks to an unborn baby when a medication is taken during pregnancy.
This medication falls into category C. No well-controlled studies have been done in humans. Therefore, this medication may be used if the potential benefits to the mother outweigh the potential risks to the unborn child.
If you are able to become pregnant, your healthcare provider should do a pregnancy test before you start treatment with Blincyto.
Females who are able to become pregnant should use an effective form of birth control during treatment with Blincyto, and for at least 48 hours after the last dose of Blincyto.
Blincyto and Lactation
Tell your healthcare provider if you are breastfeeding. It is not known if Blincyto is excreted in human milk or if it will harm your nursing baby.
You should not breastfeed during treatment with Blincyto and for at least 48 hours after your last treatment.
Blincyto will be given to you by intravenous (IV) infusion into your vein by an infusion pump.
Your healthcare provider may give you Blincyto in a hospital or clinic for the first 3 to 9 days of the first treatment cycle and for the first 2 days of the second cycle to check you for side effects.
If you receive additional treatment cycles of Blincyto or if your treatment is stopped for a period of time and restarted, you may also be treated in a hospital or clinic.
Your healthcare provider will do blood tests during treatment with Blincyto to check you for side effects.
Before you receive Blincyto, you will be given a corticosteroid medicine to help reduce infusion reactions.
It is very important to keep the area around the IV catheter clean to reduce the risk of getting an infection. Your healthcare provider will show you how to care for your catheter site.
Do not change the settings on your infusion pump, even if there is a problem with your pump or your pump alarm sounds. Call your healthcare provider or nurse right away if you have any problems with your pump or your pump alarm sounds. Any changes to your infusion pump settings may cause a dose that is too high or too low to be given.
The dose will depend on your weight, body surface area, and tolerability of side effects.
Your healthcare provider will decide the number of treatment cycles of Blincyto. Your healthcare provider may change your dose of Blincyto, delay, or completely stop treatment with Blincyto if you have certain side effects.
You will receive Blincyto by continuous IV infusion for 4 weeks (28 days), followed by a 2 week (14 days) break during which you will not receive Blincyto. This is 1 treatment cycle (42 days).
Your healthcare provider may prescribe continued therapy: You will receive Blincyto by continuous IV infusion for 4 weeks (28 days), followed by an 8 week (56 days) break during which you will not receive Blincyto. This is 1 treatment cycle (84 days).
If an overdose is suspected, seek emergency medical attention.
Blincyto FDA Warning
WARNING: CYTOKINE RELEASE SYNDROME and NEUROLOGICAL TOXICITIES
- Cytokine Release Syndrome (CRS), which may be life-threatening or fatal, occurred in patients receiving Blincyto. Interrupt or discontinue Blincyto as recommended.
- Neurological toxicities, which may be severe, life-threatening, or fatal, occurred in patients receiving Blincyto. Interrupt or discontinue Blincyto as recommended.